144 related articles for article (PubMed ID: 7881344)
1. Biomarkers in upper aerodigestive tract tumorigenesis: a review.
Shin DM; Hittelman WN; Hong WK
Cancer Epidemiol Biomarkers Prev; 1994 Dec; 3(8):697-709. PubMed ID: 7881344
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in chemoprevention for upper aerodigestive tract tumors.
Shin DM; Ro JY; Hong WK
Yonsei Med J; 1994 Jun; 35(2):113-31. PubMed ID: 8091788
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of squamous cell carcinoma of the head and neck.
Kim J; Shin DM
Histol Histopathol; 1997 Jan; 12(1):205-18. PubMed ID: 9046056
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
6. Determination of biomarkers for intermediate end points in chemoprevention trials.
Lee JS; Lippman SM; Hong WK; Ro JY; Kim SY; Lotan R; Hittelman WN
Cancer Res; 1992 May; 52(9 Suppl):2707s-2710s. PubMed ID: 1348662
[TBL] [Abstract][Full Text] [Related]
7. [Biomarkers of carcinogenesis of the upper and lower airway epithelium and the role of chemoprevention].
Soria JC; Izzo J; Mao L; Hong WK; Papadimitrakopoulou VA
Bull Cancer; 2001 Apr; 88(4):351-61. PubMed ID: 11371369
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
9. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
10. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer: chemoprevention and intermediate effect markers.
Tockman MS
IARC Sci Publ; 2001; 154():257-70. PubMed ID: 11220665
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations in mouse lung tumors: implications for cancer chemoprevention.
Herzog CR; Lubet RA; You M
J Cell Biochem Suppl; 1997; 28-29():49-63. PubMed ID: 9589349
[TBL] [Abstract][Full Text] [Related]
13. Genetic instabilities of chromosome 9, 17 and accumulation of p53 overexpression during multistage tumorigesis in head and neck cancer.
Charuruks N; Shin DM; Voravud N; Ro JY; Hong WK; Hittelman WN
J Med Assoc Thai; 1996 Dec; 79 Suppl 1():S104-12. PubMed ID: 9071074
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
15. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia.
Karakosta A; Golias Ch; Charalabopoulos A; Peschos D; Batistatou A; Charalabopoulos K
J Exp Clin Cancer Res; 2005 Dec; 24(4):505-14. PubMed ID: 16471312
[TBL] [Abstract][Full Text] [Related]
16. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
17. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
[TBL] [Abstract][Full Text] [Related]
18. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic alterations as intermediate end points in chemoprevention studies.
Conti CJ; Gimenez-Conti IB
IARC Sci Publ; 1996; (139):249-60. PubMed ID: 8923035
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of head and neck cancer.
Voravud N
J Med Assoc Thai; 1996 Mar; 79(3):185-93. PubMed ID: 8708501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
